Aspect Biosystems’ team has developed a novel bioprinting system for the fabrication of 3D biological tissue constructs. These 3D tissue constructs enable a more realistic and representative response to a given drug, compared to the standard 2D models currently being used in drug testing. They have developed a fully functioning system prototype, and initial testing has demonstrated cell viability and growth in printed 3D structures. The venture is built around this 3D bioprinting technology.
Aspect Biosystems is a Lean LaunchPad Accelerator program alumni, and is currently being mentored by the e@UBC network. Aspect also received funding from the e@UBC Seed Fund!